First Rituxan biosimilar for RA launches in USA

4 May 2020

Truxima (rituximab-abbs) injection, a biosimilar version of Roche’s (ROG: SIX) Rituxan, is now available in the USA for the treatment of:

Rheumatoid arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies; and
Granulomatosis with polyangiitis (GPA) (Wegener’s granulomatosis) and microscopic polyangiitis (MPA) in adult patients in combination with glucocorticoids.

Marketed by Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) in partnership with originator South Korea’s Celltrion Healthcare (Kosdaq: 068270), Truxima is the only biosimilar to the reference product Rituxan available to treat rheumatoid arthritis in the USA, say the companies, who launched their product with a full oncology label enjoyed by Rituxan in the USA in November last year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK